DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria

Information source: Merck KGaA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Phenylketonuria

Intervention: Sapropterin (Drug); Placebo (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Merck KGaA

Official(s) and/or principal investigator(s):
Medical Responsible, Study Director, Affiliation: Merck KGaA

Summary

This is a Phase IIa multicenter, double-blind, placebo-controlled, randomized, 2-arm pilot trial designed to assess the effect of sapropterin on cognitive abilities in young adults with Phenylketonuria (PKU) over a 26-week treatment period. This pilot trial is conducted to detect trends and generate hypotheses, relating to variability and the possible effect size on executive function, attention and processing speed. As this trial is exploratory in nature, no statistical endpoints were defined as primary or secondary.

Clinical Details

Official title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Number of subjects with adverse event

Eligibility

Minimum age: 18 Years. Maximum age: 29 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Written informed consent given before any trial-related activities are carried out

- Women or men with documented PKU diagnosed by at least two phenylalanine levels equal

or greater than 600 micromole per liter (mcmol/L)

- For women of childbearing potential: a negative urine pregnancy test is required at

screening and willingness to use a highly effective method of contraception is required during the study and follow-up periods

- Aged greater than or equal to 18 to 29 years, inclusive

- Mean blood phenylalanine levels 600 to 1000 mcmol/L during 12 months preceding

inclusion in the study. The mean should be calculated from at least 3 blood phenylalanine values over the last 12 months. Screening blood phenylalanine level can

be one of these values. There should be at least one value dated between Month - 12

and - 6 before Screening and at least one value dated between Month -6 and Screening

- An intelligence quotient (IQ) score greater than or equal to 85, assessed a maximum

of 2 years before screening with an age-appropriate Wechsler scale. If no IQ test result is available, IQ testing must be performed as part of Screening using an age-appropriate Wechsler scale before the subject can be included

- Subjects willing to comply with all study procedures, including willingness to

continue current dietary recommendations during the whole trial duration Exclusion Criteria:

- Subjects with tetrahydrobiopterin (BH4) deficiency

- Previous exposure to sapropterin or BH4 for greater than 30 days (or exposure to

sapropterin or BH4 for less than or equal to 30 days but within the previous 6 months prior to Screening visit)

- Subjects who, according to the Investigator, will not be able to comply with study

procedures and computerized neuropsychological testing

- Any significant illness which, according to the Investigator, might preclude

participation in the study (including neurological disease, cardio-vascular disease, history of seizure, predisposition to convulsions, renal or hepatic insufficiency, and active malignancy)

- Any significant illness, medication or substance abuse which, according to the

Investigator, might affect cognitive function and cognitive testing (for example, significant visual or motor impairment, history of major head trauma, history of stroke, alcoholism, drug dependency, psychological disorder requiring chronic use of psychotropic medications such as anxiolytics, antidepressants, antipsychotic medication, mood stabilizers, and hypnotics)

- Concomitant forbidden medication as described in the KuvanĀ® Summary of Product

Characteristics, namely, inhibitors of dihydrofolate reductase (for example, methotrexate, trimethoprim), medications that are known to affect nitric oxide synthesis (for example, glyceryl trinitrate, isosorbide dinitrate, sodium nitroprusside, molsidomin, phosphodiesterase type 5 inhibitors, and minoxidil), and levodopa, as it may cause increased excitability and irritability

- Known hypersensitivity to sapropterin or any ingredients in the product's

formulation, or to other approved or non-approved formulations of BH4

- Subjects who have undergone cognitive neuropsychological testing similar to that to

be performed as part of this trial with the following time limits: tasks with limited practice effect performed in the last 6 months, and tasks with important practice effect (such as tasks involving development of strategies) performed in the year preceding inclusion in the trial. Whether a task falls into one or the other category is left to Investigator judgment

- Female subjects who are pregnant or in the lactation period

- Subjects currently participating to another clinical trial or who participated in a

previous clinical trial within 30 days prior to screening

- Legal incapacity or limited legal capacity

Locations and Contacts

Research Site, Brussels, Belgium

Research Site, Egdem, Belgium

Research Site, Berlin, Germany

Research Site, Freiburg, Germany

Research Site, Leipzig, Germany

Research site, Magdeburg, Germany

Research Site, Bologna, Italy

Research Site, Milano, Italy

Research Site, Rome, Italy

Research Site, Groningen, Netherlands

Research site, Santiago de Compostela, Spain

Research site, Bern, Switzerland

Research site, Lausanne, Switzerland

Additional Information

Starting date: February 2014
Last updated: May 13, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017